Company Filing History:
Years Active: 2018-2023
Title: Abdullah Mahmood Ali: Innovator in Hematological Research
Introduction
Abdullah Mahmood Ali is a prominent inventor based in New York, NY (US). He has made significant contributions to the field of hematological research, holding a total of 7 patents. His work focuses on innovative therapies for hematological malignancies, showcasing his dedication to advancing medical science.
Latest Patents
Among his latest patents is the invention titled "CD33 exon 2 deficient donor stem cells for use with CD33 targeting agents." This patent discloses compositions and methods related to agents that target a lineage-specific cell-surface antigen and a population of hematopoietic cells deficient in this antigen for immunotherapy of hematological malignancies. Another notable patent is "Terminal erythroid differentiation as a biomarker for prognosis and treatment, and therapeutic target in myeloid malignancies." This invention utilizes terminal erythroid differentiation (TED) as a biomarker for prognosis and as a therapeutic target in myeloid malignancies, particularly myelodysplastic syndromes. It aims to identify patients at risk for poor survival outcomes who would benefit from aggressive treatment by characterizing their TED profile using protein and gene expression markers.
Career Highlights
Abdullah Mahmood Ali is affiliated with Columbia University, where he continues to engage in groundbreaking research. His work has garnered attention for its potential to improve treatment outcomes for patients with hematological disorders.
Collaborations
He has collaborated with notable colleagues in the field, including Siddhartha Mukherjee and Florence Borot. Their combined expertise contributes to the advancement of research in hematology.
Conclusion
Abdullah Mahmood Ali's innovative work in hematological research and his numerous patents reflect his commitment to improving patient care. His contributions are paving the way for new therapeutic approaches in the treatment of hematological malignancies.